clinical trial · NCT06378593
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
3H (Suzhou) Pharmaceuticals Co., Ltd.·phase2·recruiting·n = 130
Solid Tumors With FGFR2 Alterations, Adult3HP-2827
brief summary
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.
started
Jun 17, 2024
primary completion
Jun 16, 2028
completion
Jun 16, 2028
last updated
Jan 27, 2026
official title
An Open-Label, Multi-center Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol